Guangsheng Hall: Hepatitis B treatment a class of innovative drug Nairikewei GST-HG141 completes Phase III clinical trial subject enrollment.

Guangshengtang announcement: The Phase III clinical trial of innovative drug Nucleotide Ketolide GST-HG141 for the treatment of hepatitis B has recently completed enrollment of all subjects, with a total of 578 participants. GST-HG141 is used in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial for patients with chronic hepatitis B who have had a poor response to antiviral therapy. The main objective is to evaluate the efficacy and safety of GST-HG141 treatment in patients with a poor response to antiviral therapy for CHB.